Sep 04, 2019

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor

PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a monoPARP Inhibitor Cambridge, MA – …

Learn More

Aug 06, 2019

Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer

Cambridge, MA – Aug. 6, 2019 – Ribon Therapeutics, a clinical stage biotechnology company, developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …

Learn More

Jan 04, 2019

Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer

Financing led by the Novartis Venture Fund, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Celgene, and existing investors, The Column Group, Deerfield Management, …

Learn More
Join our team of experts.
Find Out More